Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Postmenopausal hormone replacement therapy increases plasmatic thromboxane beta 2.

Rute Loreto S Oliveira1, José M Aldrighi, Otávio E Gebara

  • 1Heart Institute (InCor), University of São Paulo Medical School, 05403-900 São Paulo, Brazil. ruteloreto@bol.com.br

International Journal of Cardiology
|March 18, 2005
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

iCARDIO Alliance global implementation guidelines for the management of obesity 2025 focus on prevention and treatment of cardiometabolic disease.

American journal of preventive cardiology·2026
Same author

CVOT Summit Report 2025: advances along the cardiovascular-kidney-metabolic disease continuum.

Cardiovascular diabetology·2026
Same author

Heart failure with reduced ejection fraction in Sweden: patient adherence and persistence to quadruple pharmacotherapy prescription.

European heart journal·2026
Same author

Magnitude of and outcome associated with inappropriate prescribing in heart failure with reduced ejection fraction: an analysis of 50 348 patients from the Swedish Heart Failure Registry.

European journal of heart failure·2026
Same author

iCARDIO Alliance Global Implementation Guidelines for the Management of Obesity 2025.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Pharmacologic pitfalls in heart failure: A guide to drugs that may cause or exacerbate heart failure. A European Journal of Heart Failure expert consensus document.

European journal of heart failure·2025

Hormone replacement therapy (HRT) in postmenopausal women increased thromboxane levels, suggesting a potential short-term thrombotic risk. P-selectin expression did not show significant changes with HRT.

Area of Science:

  • Endocrinology and Metabolism
  • Cardiovascular Research
  • Hematology

Background:

  • Postmenopausal hormone replacement therapy (HRT) has been linked to increased coronary heart disease risk.
  • Platelet activation, producing thromboxane A2 (TxA2), is associated with cardiovascular disease risk.

Purpose of the Study:

  • To investigate the effects of oral estrogen (exclusively or with progestin) on platelet activation in healthy postmenopausal women.

Main Methods:

  • A placebo-controlled study involving 27 postmenopausal women over 8 weeks.
  • Assessed platelet activation via P-selectin expression and plasma TxA2 (as TxB2) concentrations.

Main Results:

  • Plasma TxB2 concentrations significantly increased in the estrogen + progestin group (p=0.005).

Related Experiment Videos

  • Estrogen-only therapy showed a decrease in plasma TxB2 levels.
  • P-selectin expression did not significantly change across any treatment groups.

    • Conclusions:

    • Continuous oral estradiol with norethisterone in healthy postmenopausal women elevated plasma thromboxane, indicating potential increased short-term thrombotic risk.
    • P-selectin expression was not a sensitive marker for HRT's impact on platelet activation in this study.